Titulo:
Hemofilia A adquirida : reporte de un caso y revisión de la literatura.
.
Sumario:
La hemofilia adquirida A es una enfermedad autoinmune rara caracterizada por la presencia de autoanticuerpos contra el factor VIII de la coagulación; se manifiesta clínicamente como un síndrome hemorrágico, principalmente mucocutáneo, subcutáneo y en tejidos blandos. La etiología es idiopática en la mayoría de los casos; sin embargo, en los pacientes con patologías asociadas, las más frecuentes son enfermedades del colágeno, tumores sólidos, puerperio, tumores hematolinfoides y medicamentos. Está asociada con una morbilidad y mortalidad significativas, fundamentalmente en los pacientes de mayor edad. Describimos el caso de una mujer de 90 años, que debutó con sangrado subcutáneo severo asociado a prolongación del aPTT. En el abordaje diagnó... Ver más
Guardado en:
2256-2877
2256-2915
1
2012-09-01
73
80
Claudia Sossa Melo - 2012
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
info:eu-repo/semantics/openAccess
http://purl.org/coar/access_right/c_abf2
| id |
metarevistapublica_acho_revistacolombianadehematologiayoncologia_27_article_316 |
|---|---|
| record_format |
ojs |
| spelling |
Hemofilia A adquirida : reporte de un caso y revisión de la literatura. Acquired haemophilia A : case report and literature review. La hemofilia adquirida A es una enfermedad autoinmune rara caracterizada por la presencia de autoanticuerpos contra el factor VIII de la coagulación; se manifiesta clínicamente como un síndrome hemorrágico, principalmente mucocutáneo, subcutáneo y en tejidos blandos. La etiología es idiopática en la mayoría de los casos; sin embargo, en los pacientes con patologías asociadas, las más frecuentes son enfermedades del colágeno, tumores sólidos, puerperio, tumores hematolinfoides y medicamentos. Está asociada con una morbilidad y mortalidad significativas, fundamentalmente en los pacientes de mayor edad. Describimos el caso de una mujer de 90 años, que debutó con sangrado subcutáneo severo asociado a prolongación del aPTT. En el abordaje diagnóstico, se encontró una actividad del factor VIII marcadamente disminuida y niveles de inhibidores contra el factor VIII elevados (120 BU/ml), sin antecedente previo de trastornos de la coagulación. Se inició tratamiento con corticoides y se adicionó posteriormente ciclofosfamida, logrando disminuir los títulos del inhibidor y acortar el aPTT; no obstante, la paciente falleció a las tres semanas debido a un ataque cerebro-vascular isquémico no relacionado con el tratamiento instaurado. Acquired haemophilia A (AHA) is a very rare autoimmune disease characterized by presence of autoantibodies to circulating factor VIII; it manifests clinically as a hemorrhagic syndrome, especially with mucocutaneous, subcutaneous and soft tissues bleeding. Etiology is idiopathic in most cases; the other possible etiologies include collagen diseases, solid tumors, postpartum, hematolymphoid malignancies and drugs. Mortality depends on age, being majority of deaths in elderly people. We described a 93-years-old women presenting with a severe subcutaneous bleeding showing a prolonged partial thromboplastin time. In the diagnostic approach we found a diminished factor VIII-activity and high inhibitor titer (120 Bethesda units/ml) without a previous history of coagulation disorders. We initiated treatment with corticosteroids and then we added cyclophosphamide to achieve a reduction in the inhibitor titers and short the aPTT, however, patient died after three weeks due to an ischemic stroke unrelated to the prescribed treatment. Sossa, Claudia Jiménez, Sara Peña, Ángela Salazar, Luis Castellanos, William Gelves, Julián hemofilia adquirida A autoanticuerpos factor VIII unidades Bethesda corticosteroides ciclofosfamida factor VII recombinante activado acquired haemophilia A autoantibodies factor VIII Bethesda units corticosteroids cyclophosphamide recombinant activated factor VII 1 3 Núm. 3 , Año 2012 : Septiembre Artículo de revista Journal article 2012-09-01T00:00:00Z 2012-09-01T00:00:00Z 2012-09-01 application/pdf Asociación Colombiana de Hematología y Oncología (ACHO) Revista Colombiana de Hematología y Oncología 2256-2877 2256-2915 https://revista.acho.info/index.php/acho/article/view/316 10.51643/22562915.316 https://doi.org/10.51643/22562915.316 spa https://creativecommons.org/licenses/by-nc-sa/4.0 Claudia Sossa Melo - 2012 Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. 73 80 Knoebl P, Marco P, Baudo F, Collins P, Huth-Kühne A, Nemes L, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622-31. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M, British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012 Feb 8. doi: 10.1111/j.1365- 2141.2012.09037.x. [Epub ahead of print]. Webert KE. Acquired Hemophilia A. Semin Thromb Hemost. 2012 Sep 1. [Epub ahead of print]. Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol. 2005;80(1):55-63. Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program. 2006:432-7. Collins PW. Management of acquired haemophilia A. J Thromb Haemost. 2011;9 Suppl 1:226-35. Tufano A, Coppola A, Guida A, Cimino E, De Gregorio AM, Cerbone AM, et al. Acquired haemophilia a in the elderly: case reports. Curr Gerontol Geriatr Res. 2010;2010:927503. Sossa C, Jiménez S. Inhibidores contra los factores de la coagulación adquiridos espontáneamente: hemofilia B adquirida. Medunab. 2003;6(16):36-8. Huth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Lévesque H, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica. 2009;94(4):566-75. Tengborn L, Baudo F, Huth-Kühne A, Knoebl P, Lévesque H, Marco P, et al. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG. 2012 Aug 20. doi: 10.1111/j.1471-0528.2012.03469.x. [Epub ahead of print]. Franchini M. Postpartum acquired factor VIII inhibitors. Am J Hematol. 2006;81(10):768-73. Baudo F, Caimi T, de Cataldo F. Diagnosis and treatment of acquired haemophilia. Haemophilia. 2010;16(102):102-6. Collins P, Baudo F, Huth-Kühne A, Ingerslev J, Kessler CM, Castellano ME, et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes. 2010;3:161. Baudo F, Collins P, Huth-Kühne A, Lévesque H, Marco P, Nemes L, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood. 2012;120(1):39-46. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121(1):21-35. Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. Semin Thromb Hemost. 2012;38(5):433-46. Aouba A, Rey G, Pavillon G, Jougla E, Rothschild C, Torchet MF, et al. Deaths associated with acquired haemophilia in France from 2000 to 2009: multiple cause analysis for best care strategies. Haemophilia. 2012;18(3):339-44. Franchini M, Targher G, Montagnana M, Lippi G. Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta. 2008;395(1-2):14-8. Kitchen S, McCraw A. Diagnóstico de la hemofilia y otros trastornos de la coagulación: manual de laboratorio. 2a ed. Montreal: Federación Mundial de Hemofilia; 2010. Bowyer A, Smith J, Woolley AM, Kitchen S, Hampton KK, Maclean RM, et al. The investigation of a prolonged APTT with specific clotting factor assays is unnecessary if an APTT with Actin FS is normal. Int J Lab Hematol. 2011;33(2):212-8. Field JJ, Fenske TS, Blinder MA. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. Haemophilia. 2007;13(1):46-50. Collins PW, Percy CL. Advances in the understanding of acquired haemophilia A: implications for clinical practice. Br J Haematol. 2010;148(2):183-94. Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007;109(5):1870-7. Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost. 2012;10(8):1478-85. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost. 1997;78(6):1463-7. Baudo F, de Cataldo F, Gaidano G; Italian registry of acquired hemophilia. Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia. Haematologica. 2004;89(6):759-61. Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia. 2007;13(5):451-61. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost. 2004;2(6):899-909. Cromwell C, Aledort LM. FEIBA: a prohemostatic agent. Semin Thromb Hemost. 2012;38(3):265-7. Holme PA, Brosstad F, Tjonnfjord GE. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia. 2005;11(5):510-5. Holmström M, Tran HT, Holme PA. Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience. Haemophilia. 2012;18(4):544-9. Kasper CK. Human factor VIII for bleeding in patients with inhibitors. Vox Sang. 1999;77 Suppl 1:47-8. Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood. 1993;81(6):1513-20. Franchini M, Lippi G. The use of desmopressin in acquired haemophilia A: a systematic review. Blood Transfus. 2011;9(4):377-82. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol. 2006;133(6):591-605. Green D, Rademaker AW, Briët E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost. 1993;70(5):753-7. Collins P, Baudo F, Knoebl P, Lévesque H, Nemes L, Pellegrini F, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012;120(1):47-55. Crenier L, Ducobu J, des Grottes JM, Cerny J, Delaunoit C, Capel P. Low response to high-dose intravenous immunoglobulin in the treatment of acquired factor VIII inhibitor. Br J Haematol. 1996;95(4):750-3. Boles JC, Key NS, Kasthuri R, Ma AD. Single-center experience with rituximab as first-line immunosuppression for acquired hemophilia. J Thromb Haemost. 2011;9(7):1429-31. Pardos-Gea J, Altisent C, Parra R, Vilardell-Tarres M, Ordi-Ros J. Acquired haemophilia A. First line treatment with calcineurin inhibitors and steroid pulses: a 10-year follow-up study. Haemophilia. 2012;18(5):789-93. Lian EC, Villar MJ, Noy LI, Ruiz-Dayao Z. Acquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone. Am J Hematol. 2002;69(4):294-5. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981;45(3):200-3. Katgi A, Ataca P, Kahraman S, Piskin O, Ozcan MA, Demirkan F, et al. Ischemic stroke after recombinant factor VIIa treatment in acquired hemophilia A patient. Blood Coagul Fibrinolysis. 2012;23(1):69-70. O’Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295(3):293-8. https://revista.acho.info/index.php/acho/article/download/316/283 info:eu-repo/semantics/article http://purl.org/coar/resource_type/c_6501 info:eu-repo/semantics/publishedVersion http://purl.org/coar/version/c_970fb48d4fbd8a85 info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 Text Publication |
| institution |
ASOCIACION COLOMBIANA DE HEMATOLOGIA Y ONCOLOGIA |
| thumbnail |
https://nuevo.metarevistas.org/ASOCIACIONCOLOMBIANADEHEMATOLOGIAYONCOLOGIA/logo.png |
| country_str |
Colombia |
| collection |
Revista Colombiana de Hematología y Oncología |
| title |
Hemofilia A adquirida : reporte de un caso y revisión de la literatura. |
| spellingShingle |
Hemofilia A adquirida : reporte de un caso y revisión de la literatura. Sossa, Claudia Jiménez, Sara Peña, Ángela Salazar, Luis Castellanos, William Gelves, Julián hemofilia adquirida A autoanticuerpos factor VIII unidades Bethesda corticosteroides ciclofosfamida factor VII recombinante activado acquired haemophilia A autoantibodies factor VIII Bethesda units corticosteroids cyclophosphamide recombinant activated factor VII |
| title_short |
Hemofilia A adquirida : reporte de un caso y revisión de la literatura. |
| title_full |
Hemofilia A adquirida : reporte de un caso y revisión de la literatura. |
| title_fullStr |
Hemofilia A adquirida : reporte de un caso y revisión de la literatura. |
| title_full_unstemmed |
Hemofilia A adquirida : reporte de un caso y revisión de la literatura. |
| title_sort |
hemofilia a adquirida : reporte de un caso y revisión de la literatura. |
| title_eng |
Acquired haemophilia A : case report and literature review. |
| description |
La hemofilia adquirida A es una enfermedad autoinmune rara caracterizada por la presencia de autoanticuerpos contra el factor VIII de la coagulación; se manifiesta clínicamente como un síndrome hemorrágico, principalmente mucocutáneo, subcutáneo y en tejidos blandos. La etiología es idiopática en la mayoría de los casos; sin embargo, en los pacientes con patologías asociadas, las más frecuentes son enfermedades del colágeno, tumores sólidos, puerperio, tumores hematolinfoides y medicamentos. Está asociada con una morbilidad y mortalidad significativas, fundamentalmente en los pacientes de mayor edad. Describimos el caso de una mujer de 90 años, que debutó con sangrado subcutáneo severo asociado a prolongación del aPTT. En el abordaje diagnóstico, se encontró una actividad del factor VIII marcadamente disminuida y niveles de inhibidores contra el factor VIII elevados (120 BU/ml), sin antecedente previo de trastornos de la coagulación. Se inició tratamiento con corticoides y se adicionó posteriormente ciclofosfamida, logrando disminuir los títulos del inhibidor y acortar el aPTT; no obstante, la paciente falleció a las tres semanas debido a un ataque cerebro-vascular isquémico no relacionado con el tratamiento instaurado.
|
| description_eng |
Acquired haemophilia A (AHA) is a very rare autoimmune disease characterized by presence of autoantibodies to circulating factor VIII; it manifests clinically as a hemorrhagic syndrome, especially with mucocutaneous, subcutaneous and soft tissues bleeding. Etiology is idiopathic in most cases; the other possible etiologies include collagen diseases, solid tumors, postpartum, hematolymphoid malignancies and drugs. Mortality depends on age, being majority of deaths in elderly people. We described a 93-years-old women presenting with a severe subcutaneous bleeding showing a prolonged partial thromboplastin time. In the diagnostic approach we found a diminished factor VIII-activity and high inhibitor titer (120 Bethesda units/ml) without a previous history of coagulation disorders. We initiated treatment with corticosteroids and then we added cyclophosphamide to achieve a reduction in the inhibitor titers and short the aPTT, however, patient died after three weeks due to an ischemic stroke unrelated to the prescribed treatment.
|
| author |
Sossa, Claudia Jiménez, Sara Peña, Ángela Salazar, Luis Castellanos, William Gelves, Julián |
| author_facet |
Sossa, Claudia Jiménez, Sara Peña, Ángela Salazar, Luis Castellanos, William Gelves, Julián |
| topicspa_str_mv |
hemofilia adquirida A autoanticuerpos factor VIII unidades Bethesda corticosteroides ciclofosfamida factor VII recombinante activado |
| topic |
hemofilia adquirida A autoanticuerpos factor VIII unidades Bethesda corticosteroides ciclofosfamida factor VII recombinante activado acquired haemophilia A autoantibodies factor VIII Bethesda units corticosteroids cyclophosphamide recombinant activated factor VII |
| topic_facet |
hemofilia adquirida A autoanticuerpos factor VIII unidades Bethesda corticosteroides ciclofosfamida factor VII recombinante activado acquired haemophilia A autoantibodies factor VIII Bethesda units corticosteroids cyclophosphamide recombinant activated factor VII |
| citationvolume |
1 |
| citationissue |
3 |
| citationedition |
Núm. 3 , Año 2012 : Septiembre |
| publisher |
Asociación Colombiana de Hematología y Oncología (ACHO) |
| ispartofjournal |
Revista Colombiana de Hematología y Oncología |
| source |
https://revista.acho.info/index.php/acho/article/view/316 |
| language |
spa |
| format |
Article |
| rights |
https://creativecommons.org/licenses/by-nc-sa/4.0 Claudia Sossa Melo - 2012 Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 |
| references |
Knoebl P, Marco P, Baudo F, Collins P, Huth-Kühne A, Nemes L, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622-31. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M, British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012 Feb 8. doi: 10.1111/j.1365- 2141.2012.09037.x. [Epub ahead of print]. Webert KE. Acquired Hemophilia A. Semin Thromb Hemost. 2012 Sep 1. [Epub ahead of print]. Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol. 2005;80(1):55-63. Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program. 2006:432-7. Collins PW. Management of acquired haemophilia A. J Thromb Haemost. 2011;9 Suppl 1:226-35. Tufano A, Coppola A, Guida A, Cimino E, De Gregorio AM, Cerbone AM, et al. Acquired haemophilia a in the elderly: case reports. Curr Gerontol Geriatr Res. 2010;2010:927503. Sossa C, Jiménez S. Inhibidores contra los factores de la coagulación adquiridos espontáneamente: hemofilia B adquirida. Medunab. 2003;6(16):36-8. Huth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Lévesque H, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica. 2009;94(4):566-75. Tengborn L, Baudo F, Huth-Kühne A, Knoebl P, Lévesque H, Marco P, et al. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG. 2012 Aug 20. doi: 10.1111/j.1471-0528.2012.03469.x. [Epub ahead of print]. Franchini M. Postpartum acquired factor VIII inhibitors. Am J Hematol. 2006;81(10):768-73. Baudo F, Caimi T, de Cataldo F. Diagnosis and treatment of acquired haemophilia. Haemophilia. 2010;16(102):102-6. Collins P, Baudo F, Huth-Kühne A, Ingerslev J, Kessler CM, Castellano ME, et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes. 2010;3:161. Baudo F, Collins P, Huth-Kühne A, Lévesque H, Marco P, Nemes L, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood. 2012;120(1):39-46. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121(1):21-35. Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. Semin Thromb Hemost. 2012;38(5):433-46. Aouba A, Rey G, Pavillon G, Jougla E, Rothschild C, Torchet MF, et al. Deaths associated with acquired haemophilia in France from 2000 to 2009: multiple cause analysis for best care strategies. Haemophilia. 2012;18(3):339-44. Franchini M, Targher G, Montagnana M, Lippi G. Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta. 2008;395(1-2):14-8. Kitchen S, McCraw A. Diagnóstico de la hemofilia y otros trastornos de la coagulación: manual de laboratorio. 2a ed. Montreal: Federación Mundial de Hemofilia; 2010. Bowyer A, Smith J, Woolley AM, Kitchen S, Hampton KK, Maclean RM, et al. The investigation of a prolonged APTT with specific clotting factor assays is unnecessary if an APTT with Actin FS is normal. Int J Lab Hematol. 2011;33(2):212-8. Field JJ, Fenske TS, Blinder MA. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. Haemophilia. 2007;13(1):46-50. Collins PW, Percy CL. Advances in the understanding of acquired haemophilia A: implications for clinical practice. Br J Haematol. 2010;148(2):183-94. Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007;109(5):1870-7. Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost. 2012;10(8):1478-85. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost. 1997;78(6):1463-7. Baudo F, de Cataldo F, Gaidano G; Italian registry of acquired hemophilia. Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia. Haematologica. 2004;89(6):759-61. Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia. 2007;13(5):451-61. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost. 2004;2(6):899-909. Cromwell C, Aledort LM. FEIBA: a prohemostatic agent. Semin Thromb Hemost. 2012;38(3):265-7. Holme PA, Brosstad F, Tjonnfjord GE. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia. 2005;11(5):510-5. Holmström M, Tran HT, Holme PA. Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience. Haemophilia. 2012;18(4):544-9. Kasper CK. Human factor VIII for bleeding in patients with inhibitors. Vox Sang. 1999;77 Suppl 1:47-8. Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood. 1993;81(6):1513-20. Franchini M, Lippi G. The use of desmopressin in acquired haemophilia A: a systematic review. Blood Transfus. 2011;9(4):377-82. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol. 2006;133(6):591-605. Green D, Rademaker AW, Briët E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost. 1993;70(5):753-7. Collins P, Baudo F, Knoebl P, Lévesque H, Nemes L, Pellegrini F, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012;120(1):47-55. Crenier L, Ducobu J, des Grottes JM, Cerny J, Delaunoit C, Capel P. Low response to high-dose intravenous immunoglobulin in the treatment of acquired factor VIII inhibitor. Br J Haematol. 1996;95(4):750-3. Boles JC, Key NS, Kasthuri R, Ma AD. Single-center experience with rituximab as first-line immunosuppression for acquired hemophilia. J Thromb Haemost. 2011;9(7):1429-31. Pardos-Gea J, Altisent C, Parra R, Vilardell-Tarres M, Ordi-Ros J. Acquired haemophilia A. First line treatment with calcineurin inhibitors and steroid pulses: a 10-year follow-up study. Haemophilia. 2012;18(5):789-93. Lian EC, Villar MJ, Noy LI, Ruiz-Dayao Z. Acquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone. Am J Hematol. 2002;69(4):294-5. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981;45(3):200-3. Katgi A, Ataca P, Kahraman S, Piskin O, Ozcan MA, Demirkan F, et al. Ischemic stroke after recombinant factor VIIa treatment in acquired hemophilia A patient. Blood Coagul Fibrinolysis. 2012;23(1):69-70. O’Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295(3):293-8. |
| type_driver |
info:eu-repo/semantics/article |
| type_coar |
http://purl.org/coar/resource_type/c_6501 |
| type_version |
info:eu-repo/semantics/publishedVersion |
| type_coarversion |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| type_content |
Text |
| publishDate |
2012-09-01 |
| date_accessioned |
2012-09-01T00:00:00Z |
| date_available |
2012-09-01T00:00:00Z |
| url |
https://revista.acho.info/index.php/acho/article/view/316 |
| url_doi |
https://doi.org/10.51643/22562915.316 |
| issn |
2256-2877 |
| eissn |
2256-2915 |
| doi |
10.51643/22562915.316 |
| citationstartpage |
73 |
| citationendpage |
80 |
| url2_str_mv |
https://revista.acho.info/index.php/acho/article/download/316/283 |
| _version_ |
1811200921753878528 |